European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU
On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…
Quidel received Emergency Use Authorization for QuickVue SARS rapid antigen test for COVID-19 diagnosis
On Dec. 21, 2020, Quidel announced that it had received Emergency Use Authorization from the U.S. Food and…
CDC’s ACIP announced interim recommendation for use of Moderna COVID-19 Vaccine
On Dec. 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics
FDA approved first adjuvant therapy for most common type of lung cancer
On Dec. 18, 2020, the the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) as the…
National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates
On Dec. 18, 2020, the National Research Council of Canada (NRC) announced it was providing advisory services and…
FDA issued Emergency Use Authorization for second COVID-19 vaccine
On Dec. 18, 2020, the FDA issued an emergency use authorization (EUA) for the second vaccine for the…
Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
On Dec. 18, 2020, Eli Lilly announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in…
EC exercised option for additional 80 million doses of Moderna’s COVID-19 vaccine candidate
On Dec. 18, 2020, Moderna announced that the European Commission (EC) had exercised its option to purchase an…
Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.
On Dec. 18, 2020, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
CDC Advisory Committee on Immunization Practices recommended vaccination with Moderna’s COVID-19 vaccine
On Dec. 18, 2020, Moderna announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on…
Biotechnology | COVID-19 | FDA | Vaccine
Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.
On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
Novavax announced agreement with government of New Zealand for 107 million doses of COVID-19 vaccine
On Dec. 16, 2020, Novavax announced an Advance Purchase Agreement with the government of New Zealand for the…
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
AXIM Biotechnologies completed successful Covid-19 live virus test and filed amended EUA
On Dec. 15, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…
Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing
On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of…
Biotechnology | CRISPR | FDA | Therapeutics
CIRM-funded project targeting sickle cell disease received green light for clinical trial
On Dec.14, 2020, the US Food and Drug Administration (FDA) announced they had granted Investigational New Drug (IND)…
Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm
On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of…
Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19
On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…
CDC’s ACIP issued interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for prevention of COVID-19.
On Dec. 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of…
U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccine
On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
ImmunityBio’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airways
On Dec. 10, 2020, ImmunityBio announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates…
Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescents
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
Switzerland exercised increased option for 7.5 million doses of mRNA vaccine against COVID-19 (mRNA-1273)
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
Mount Sinai researchers advanced universal influenza virus vaccine
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…